HeartBeam Study Shows Comparable Accuracy Between Portable 3D ECG System and Standard 12-Lead ECG
TL;DR
HeartBeam's compact 3D ECG device offers comparable accuracy to standard 12-lead systems, providing a competitive edge in portable cardiac monitoring for broader market adoption.
HeartBeam's deep learning algorithms process 3D ECG signals from three non-coplanar directions to synthesize 12-lead equivalents with 94.5% accuracy versus 95.5% for standard ECGs.
HeartBeam's portable technology enables advanced cardiac monitoring outside medical facilities, improving early detection and access to care for better patient outcomes worldwide.
HeartBeam's FDA-cleared 3D ECG device uses innovative deep learning to match standard 12-lead accuracy in detecting arrhythmias with just a compact, cable-free unit.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam Inc. (NASDAQ: BEAT) has reported significant study results showing no meaningful differences in detecting atrial fibrillation, atrial flutter, and sinus rhythm between its HeartBeam System with deep learning algorithms and standard 12-lead electrocardiograms. The data, presented at HRX Live 2025 in Atlanta by Dr. Joshua Lampert of Mount Sinai Heart, involved 201 patients and demonstrated high accuracy rates of 94.5% for the HeartBeam System compared to 95.5% for conventional 12-lead ECGs.
The findings highlight the potential of HeartBeam's compact, three-dimensional device to bring advanced cardiac monitoring capabilities to environments where traditional 12-lead ECGs may be impractical or unavailable. This technological advancement could significantly impact cardiac care delivery by enabling accurate arrhythmia detection outside of medical facilities, potentially allowing for earlier intervention and improved patient outcomes.
HeartBeam's platform technology represents a breakthrough in portable cardiac monitoring, creating the first cable-free device capable of collecting ECG signals in three dimensions from non-coplanar directions and synthesizing these signals into a 12-lead ECG equivalent. The company plans to use these study results to support future submissions to the U.S. Food and Drug Administration, building upon the FDA clearance already received for arrhythmia assessment in December 2024. Additional information about the company's technology and developments is available at https://ibn.fm/BEAT.
The implications of this research extend beyond clinical settings to potentially transform how cardiac conditions are monitored in home environments, remote locations, and during emergency situations. By providing physicians with actionable heart intelligence outside medical facilities, the technology could help identify cardiac health trends and acute conditions more efficiently, directing patients to appropriate care sooner. The company's extensive intellectual property portfolio, comprising over 20 issued patents related to technology enablement, underscores the innovative nature of this approach to cardiac care management.
Curated from InvestorBrandNetwork (IBN)
